Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Dent

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Current Oncology (Toronto, Ont.)|August 10, 2012
Excision of the primary tumour in patients with metastatic breast cancer: a clinical dilemmaS Samiee, P Berardi, N Bouganim, et al.
Current Oncology (Toronto, Ont.)|June 23, 2016
Can the referring surgeon enhance accrual of breast cancer patients to medical and radiation oncology trials? The ENHANCE studyA Arnaout, I Kuchuk, N Bouganim, et al.
Current Oncology (Toronto, Ont.)|August 13, 2009
The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancerS Dent, Sh Verma, J Latreille, et al.
Orthopaedic Journal of Sports Medicine|June 9, 2022
Epidemiology and Outcomes of Ankle Injuries in the National Football LeagueSohil S Desai, Craig S Dent, Blake H Hodgens, et al.
Journal of Medical Economics|October 28, 2014
Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in CanadaC L Attard, A N Pepper, S T Brown, et al.
Current Oncology (Toronto, Ont.)|October 29, 2009
The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancersJ Lemieux, M Clemons, L Provencher, et al.
Current Oncology (Toronto, Ont.)|August 11, 2010
Optimizing the management of HER2-positive early breast cancer: the clinical realitySu Verma, S Lavasani, J Mackey, et al.
ESMO Open|June 3, 2025
Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship careC Dauccia, E Agostinetto, L Arecco, et al.
AJR. American Journal of Roentgenology|August 1, 1995
Quantification of the volume of articular cartilage in the metacarpophalangeal joints of the hand: accuracy and precision of three-dimensional MR imagingC G Peterfy, C F van Dijke, Y Lu, et al.
Breast Cancer Research and Treatment|December 9, 2015
A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancerC Jacobs, I Kuchuk, N Bouganim, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Current Oncology (Toronto, Ont.)|August 10, 2012
Excision of the primary tumour in patients with metastatic breast cancer: a clinical dilemmaS Samiee, P Berardi, N Bouganim, et al.
Current Oncology (Toronto, Ont.)|June 23, 2016
Can the referring surgeon enhance accrual of breast cancer patients to medical and radiation oncology trials? The ENHANCE studyA Arnaout, I Kuchuk, N Bouganim, et al.
Current Oncology (Toronto, Ont.)|August 13, 2009
The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancerS Dent, Sh Verma, J Latreille, et al.
Orthopaedic Journal of Sports Medicine|June 9, 2022
Epidemiology and Outcomes of Ankle Injuries in the National Football LeagueSohil S Desai, Craig S Dent, Blake H Hodgens, et al.
Journal of Medical Economics|October 28, 2014
Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in CanadaC L Attard, A N Pepper, S T Brown, et al.
Current Oncology (Toronto, Ont.)|October 29, 2009
The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancersJ Lemieux, M Clemons, L Provencher, et al.
Current Oncology (Toronto, Ont.)|August 11, 2010
Optimizing the management of HER2-positive early breast cancer: the clinical realitySu Verma, S Lavasani, J Mackey, et al.
ESMO Open|June 3, 2025
Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship careC Dauccia, E Agostinetto, L Arecco, et al.
AJR. American Journal of Roentgenology|August 1, 1995
Quantification of the volume of articular cartilage in the metacarpophalangeal joints of the hand: accuracy and precision of three-dimensional MR imagingC G Peterfy, C F van Dijke, Y Lu, et al.
Breast Cancer Research and Treatment|December 9, 2015
A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancerC Jacobs, I Kuchuk, N Bouganim, et al.
Pageof 5